Delivery Order SPE2DB22D2206-SPE2DB25FJS47
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,420.49 to AmerisourceBergen Drug Corp for the supply of UBRELVY (an FDA-approved migraine treatment) in 100 mg tablet form on August 20, 2025, with completion expected by August 21, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of UBRELVY 50 mg tablets (10-count unit dose packaging) with a ceiling value of $4,919.80 and an ultimate completion date of August 4, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,487.22 to AmerisourceBergen Drug Corp for the supply of UBRELVY 100 mg tablets (16 unit dose tablets), a migraine treatment medication. Issued on August 11, 2025, with an ultimate completion date of August 12, 2025, this firm fixed-price delivery order represents a non-competitive purchase executed under an existing contract vehicle. The order will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This order, valued at $2,135.70, represents a firm fixed price delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a $15,567.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of UBRELVY 100 mg tablets (unit dose, 10s). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription migraine treatment, indicating this delivery order supports military or federal...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for UBRELVY 100 mg tablet unit dose packs (16-count) with a ceiling value of $1,488.85. This competitive award, executed under firm fixed-price terms with no set-aside designation, is scheduled for completion by September 2, 2025. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $2,126.74 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose tablets) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed price contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, valued at $999,999,999.00 and running through December 2026....
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJS47Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,074.95 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of UBRELVY (an FDA-approved migraine treatment) in 100 mg tablet form. This firm fixed-price delivery order, which is due for completion by September 2, 2025, represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio. The award was made through open competition with no set-aside designation, underscoring the vendor's capability to compete effectively for federal medical procurement needs. This delivery order is a child contract under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs. The company, headquartered in Conshohocken, Pennsylvania, functions as a critical pharmaceutical distributor for federal medical procurement, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through this flexible contract mechanism that facilitates rapid fulfillment of military pharmaceutical requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 8/29/25 |